Inauguration of MRI Facility and Health Service Initiative at Bhayangkara Kediri Hospital, Featuring DNA Testing Services in Collaboration with Regene Genomics

December 24, 2024 03:38 PM AEDT | By Cision

Inauguration of MRI Facility and Health Service Initiative at Bhayangkara Kediri Hospital, Featuring DNA Testing Services in Collaboration with Regene Genomics — Image source: Kalkine Media

Recent News

Health In Tech Announces Closing of Initial Public Offering

CES 2025 Preview: TESSAN to Showcase Charging Solutions for Enhanced C...

TESSAN Teams Up with One Tree Planted to Launch Global Tree Planting I...

Entergy Surprises Customers and Spreads Holiday Joy Through Annual “Op...

JAKARTA and KEDIRI, Indonesia, Dec. 24, 2024 /PRNewswire/ -- Bhayangkara Kediri Hospital inaugurated its new MRI service building and laid the cornerstone for a new service facility, marking a significant step forward in enhancing healthcare services in Kediri and surrounding areas.

The festive inauguration ceremony was led by Head of the Central Police Hospital, Police Brigadier General dr. Prima Heru Y, M.Kes., M.H., accompanied by the East Java Regional Police Medical and Health Central Team. The event, held at Bhayangkara Kediri Hospital, Jl. Kombes Duryat No. 17, Kediri City, was attended by several prominent figures, including Deputy Chief of the Kediri Resort Police Police Commissioner Dodik Tri Hendro S, S.H., S.I.K., M.I.K., Acting Mayor of Kediri represented by City Secretary Bagus Alit, and Chairman of PCNU Kediri City KH Abubakar Abdul Djalil (Gus AB).

In his speech, dr. Prima Heru stated that Bhayangkara Kediri Hospital is progressing rapidly with the addition of services such as the 3 Tesla MRI, DNA testing, executive polyclinic, aesthetic polyclinic, cardiac catheterisation, and more. The hospital aims to become a one-stop service facility so police personnel and the general public no longer need referrals to other hospitals. He expressed his hope that Bhayangkara Kediri Hospital will continue to grow and succeed.

One of the key moments of the inauguration was the announcement of a strategic collaboration between Bhayangkara Kediri Hospital and Regene Genomics, the most comprehensive DNA testing service provider in Indonesia, developed by local talent.

This collaboration aims to provide DNA and genomic testing services that can enhance lifestyles, improve diagnostic accuracy, support health planning, and aid in disease prevention for individuals, aligned with precision medicine. During the event, several attending officials personally tried Regene Genomics' DNA testing services as a symbolic gesture to mark the start of this collaboration.

The Head of Bhayangkara Kediri Hospital, Police Commissioner drg. Agung Hadi Wijanarko, Sp.BM, stated, "This collaboration is a significant step forward in delivering advanced, technology-based healthcare services to the community. With the new building facility and support from Regene Genomics, we are optimistic about providing more personalized and targeted healthcare solutions."

Regene Genomics is a DNA and genomic testing service provider developed by Indonesian talent, and recognized as the most comprehensive in Indonesia. Leveraging the latest Microarray Illumina technology, Regene offers a variety of benefits, including:

Nutrition and Diet: Customizing diets and nutritional plans based on genetic profiles.
Cancer and Infections: Identifying future risks of cancer and infections.
Dermatology: Enhancing beauty clinic capabilities with DNA-based precision skin health solutions.
General Diseases: Detecting risks of critical diseases early, such as diabetes and heart disease.
Mental Health: Analyzing genetic factors influencing stress, fitness, and lifestyle.
Talents and Abilities: Helping parents understand their children's potential to support optimal talent development.

"Regene Genomics is proud to be part of the healthcare transformation at Bhayangkara Kediri Hospital. We believe DNA testing will become a vital solution in providing more personalized healthcare services," said the Chief Scientific Officer of Regene Genomics, Police Commissioner (Ret.) Drs. Putut Tjahjo Widodo, DFM, M.Si.

The inauguration of this new building and the collaboration with Regene Genomics demonstrate Bhayangkara Kediri Hospital's commitment to continuous innovation in delivering top-quality healthcare services to the general public. This step is expected to inspire other healthcare institutions to adopt genomic services to improve the health and quality of life of the Indonesian population.

Contact detail RS Bhayangkara:
Rumah Sakit Bhayangkara Kediri
Jl. Kombes Pol Duryat No.17, Dandangan, Kec. Kota, Kota Kediri, Jawa Timur 64122
Telepon: (0354) 671100

Contact detail Regene Genomics:
Regene Genomics (PT. Regene Artifisial Intelijen)
Blok TB No.35, Jl. Metro Pondok Indah, Pd. Pinang, Kec. Kby. Lama, Jakarta, Daerah Khusus Ibukota Jakarta 12310
Telepon: 0851-8682-3500, Website: regene.ai

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Full Name

Mobile

By submitting your details above and clicking on the 'Download Report' button, you confirm that you are happy for one of the representatives of Kalkine Media or its group entities to contact you to discuss the services, consent to - our Terms & Conditions, and to receive marketing offers, including to be contacted by email or phone, as set out in our Privacy Policy. Any calls will be made by Kalkine group's telemarketing entities on our behalf or on behalf of Kalkine group entities.

Markets

Disclaimer

Recent Articles

1

2

3

4

5

Investing Tips

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27